<?xml version="1.0" encoding="UTF-8"?>
<p>As cardiac glycosides, the original bioactivity attributed to bufadienolides is their cardiotonic activity, acting as inhibitors of the sodium pump at the myocardial tissue [
 <xref rid="B116-pharmaceuticals-13-00444" ref-type="bibr">116</xref>]. However, its reduced therapeutic window conditions its efficacy, allowing eventual cardiotoxic events due to overdosage [
 <xref rid="B117-pharmaceuticals-13-00444" ref-type="bibr">117</xref>]. In fact, the accidental consumption of 
 <italic>Bryophyllum</italic> species by different mammals is one of the leading causes of cattle mortality in Africa [
 <xref rid="B118-pharmaceuticals-13-00444" ref-type="bibr">118</xref>], with reporting episodes of stroke, subendocardial hemorrhages, and heart tissue necrosis [
 <xref rid="B119-pharmaceuticals-13-00444" ref-type="bibr">119</xref>]. The biosynthesis of bufadienolides is a plant defensive mechanism against insect and herbivore attacks. They have already been reported as effective insecticidal compounds [
 <xref rid="B31-pharmaceuticals-13-00444" ref-type="bibr">31</xref>].
</p>
